Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved audited standalone and consolidated financial results for Q4 and FY ended 31 March 2025. Standalone FY25 revenue fell sharply to Rs 5,254.82 lakhs from Rs 11,816.81 lakhs in FY24, with net profit of Rs 36.39 lakhs vs Rs 136.99 lakhs last year; Q4 standalone was a loss of Rs 48.03 lakhs. Consolidated FY25 revenue was Rs 11,505.95 lakhs with net profit of Rs 63.64 lakhs. The statutory auditor (M/s. M.M. Reddy & Co.) issued an unmodified opinion. Two new directors were appointed (Mrs. Pammi Mounika Reddy as Non-Executive Director and Mrs. Khushboo Joshi as Independent Director for 5 years), while Independent Director Mr. Ravikanth Kancherla and Non-Executive Director Mrs. Srilatha Burugu resigned. New internal and secretarial auditors were also appointed. The board authorized exploring fund-raising of up to USD 50 million through equity, convertible bonds, FCCBs, or other instruments, and authorized the MD to pursue acquisitions and inorganic growth.
For shareholders, the weak FY25 performance, especially the steep revenue drop on a standalone basis and the Q4 loss, is a concern. However, the proposed fund-raising of up to USD 50 million and acquisition-focused authorization signal an aggressive growth pivot that could dilute existing shareholders depending on the route (preferential, QIP, etc.). Director churn at the same sitting (two exits, two appointments) is notable but partly routine given committee reconstitution.